Skip to main content
Back
Watch Compare

EUPRAXIA PHARMACEUTICALS INC.

Data quality: 100%
EPRX
Nasdaq Manufacturing Chemicals
$6.86
▼ $0.22 (-3.11%)
Mkt Cap: 433.60 M
Price
$7.05
Mkt Cap
433.60 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Negative free cash flow of -28.55 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-66.83%
Below sector avg (-53.34%)
ROICN/A
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio15.12
Interest CoverageN/A

Valuation

PE (TTM)
-11.24
Below sector avg (-1.47)
P/B Ratio5.29
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -11.2 -1.5
P/B 5.3 1.6
ROE % -66.8 -53.3
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Analyst Price Target

7 analysts
Buy
Current
$6.86
+109.8%
Target
$14.39
$11.00
$14.00
$19.00
Forecast
Forward P/E -10.68
Forward EPS -$0.64
Est. Revenue 15.91 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$0.64
-$1.04 – $0.36
 15.91 M 8
FY2026 -$0.72
-$0.96 – -$0.50
 0.0 9

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$0.16 -$0.37 -133.3%
Q32025 -$0.19 -$0.19 +1.0%
Q22025 -$0.19 -$0.26 -40.5%
Q12025 -$0.17 -$0.21 -26.0%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -38.58 M
ROE -66.83% ROA -63.71%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -28.55 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 15.12
Interest Coverage N/A Asset Turnover 0.00
Working Capital 79.47 M Tangible Book Value 82.04 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -11.24 Forward P/E N/A
P/B Ratio 5.29 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -6.58%
Market Cap 433.60 M Enterprise Value 353.03 M
Per Share
EPS (Diluted TTM) -1.03 Revenue / Share 0.00
FCF / Share -0.46 OCF / Share -0.46
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 74.02%
SBC-Adj. FCF -37.31 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023
Revenue 0.0 0.0 0.0
Net Income -38.58 M -25.50 M -28.22 M
EPS (Diluted) -1.03 -0.76 -1.17
Gross Profit — — —
Operating Income — — —
EBITDA — — —
R&D Expenses 21.33 M 16.08 M 20.56 M
SG&A Expenses — — —
D&A — — —
Interest Expense 0.0 603,573.0 1.17 M
Income Tax 19,091.0 1,804.0 36,423.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023
Total Assets 86.15 M 34.94 M 20.27 M
Total Liabilities 5.70 M 3.10 M 19.37 M
Shareholders' Equity 82.04 M 33.40 M 2.22 M
Total Debt — — —
Cash & Equivalents 80.56 M 33.10 M 19.34 M
Current Assets 85.10 M 34.44 M 19.80 M
Current Liabilities 5.63 M 3.10 M 19.37 M